Merck KGaA (Xetra:MRK) and Pfizer Inc. (NYSE:PFE) discontinued the Phase III JAVELIN Ovarian 100 trial of Bavencio avelumab as first-line treatment of ovarian cancer after a planned interim analysis showed that the PD-L1 inhibitor would miss the primary endpoint of improving progression-free survival (PFS) vs. platinum-based chemotherapy alone.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,